The EDICT study, employing diabetes medications (GLP-1 receptor agonist, pioglitazone, metformin) that correct the basic underlying pathophysiologic defects present in type 2 diabetes, convincingly demonstrated that combination therapy produces a greater and more durable reduction in HbA1c than the treat-to-fail approach using diabetes medications (sulfonylureas, metformin, insulin) that do not correct the basic metabolic and cellular defects (insulin resistance and beta-cell dysfunction) present in type 2 diabetes patients
Still, several indirect pathways provide plausible explanations: Rapid changes in body composition and biomechanics after weight loss
Non-coding RNA regulators of diabetic polyneuropathy
In May 2022, Mounjaro was approved by the FDA for the treatment of type 2 diabetes, though many people have also used it off-label for weight loss
None of the three options bills insurance directly all are cash-pay
Several publications use different spellings and incomplete chemical descriptions
